Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes

A Contract Award Notice
by DEPARTMENT OF HEALTH AND SOCIAL CARE

Source
Contracts Finder
Type
Contract (Products)
Duration
14.5 month
Value
£1
Sector
HEALTH
Published
18 Nov 2021
Delivery
13 Oct 2021 to 31 Dec 2022
Deadline
12 Oct 2021 23:00

Concepts

Location

Geochart for 1 buyers and 1 suppliers

1 buyer

1 supplier

Description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community. This agreement is for the procurement of 480,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK's multi-layered approach to COVID-19.

Award Detail

1 Merck Sharpe & Dohme (Moorgate)
  • Value: £1

CPV Codes

  • 33600000 - Pharmaceutical products

Other Information

Annex D1 https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/8d000000GwQm/KzY1DGQKCVY... Final - Antiviral Supply Agreement Redacted https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/8d000000Gxix/mkiD05z4m1x...

Reference

Domains